GLUE · Monte Rosa Therapeutics, Inc.

$15.50 -0.34 (-2.15%) At close · Aug 14

Market Cap

$1.32B

85.31M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Markus Warmuth	Chief Executive Officer	$650,000	—	$910,080	$3,043,648	$429,000	—	$5,032,728
Filip Janku	M.D., Ph.D. Chief Medical Officer	$520,000	—	$255,960	$852,221	$299,600	$14,000	$1,941,781
Phil Nickson	Chief Business and Legal Officer	$520,000	—	$255,960	$852,221	$299,600	$14,000	$1,941,781

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Markus Warmuth	Chief Executive Officer	$616,400	—	—	$1,469,981	$354,430	—	$2,440,811
Phil Nickson	Chief Business and Legal Officer	$473,611	—	—	$582,827	$217,390	$13,800	$1,287,628
Filip Janku	M.D., Ph.D. Chief Medical Officer	$500,000	—	—	$514,069	$230,000	$13,800	$1,257,869

Executive changes

Person	Role	Change	Effective	Filed
Matthew Bowen	Corporate Controller and Principal Accounting Officer	Appointed	2026-04-03	2026-02-10
Edmund Dunn	SVP, Corporate Controller and Principal Accounting Officer	Retired	2026-04-03	2026-02-10
Eric A. Hughes, M.D., Ph.D.	Class III director	Appointed	2024-12-11	2024-12-13
Jennifer Champoux	Chief Operating Officer	Appointed	2024-05-28	2024-05-30
Owen Wallace	Chief Scientific Officer	Resigned	2024-05-17	2024-05-02
Anthony M. Manning, Ph.D.	Class II director	Appointed	2023-07-25	2023-07-26
Jan Skvarka, Ph.D., MBA	Class I director	Appointed	2023-03-23	2023-03-23

Key facts CIK 1826457 CUSIP 61225M102 13F (30d) 188 filings 184 filers Visit website Investor relations